Showing results (71-80 of 128) with videos related to

Sort By:
Pageof 13
Investigational New Drugs|February 12, 2010
Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I studyCheryl Ho, Randeep Sangha, Laurel Beckett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2022
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)Philip C Mack, Jieling Miao, Mary W Redman, et al.
Cancer Research|April 3, 2008
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancerOliver Gautschi, Clifford G Tepper, Phillip R Purnell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2013
Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536Edward S Kim, James Moon, Roy S Herbst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2003
Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative studyPrimo N Lara, Paul Frankel, Philip C Mack, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327)Primo N Lara, Kari Chansky, Angela M Davies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2010
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancerTanya B Dorff, Bryan Goldman, Jacek K Pinski, et al.
JCO Precision Oncology|May 26, 2021
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung CancerCaroline E McCoach, Aiming Yu, David R Gandara, et al.
Cancer|May 5, 2020
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 casesPhilip C Mack, Kimberly C Banks, Carin R Espenschied, et al.
Journal of the National Cancer Institute|February 26, 2014
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421Primo N Lara, Benjamin Ely, David I Quinn, et al.
Pageof 13